Bayer Norden: Bayer and Schering Integrated in Scandinavia

02-Apr-2007
Bayer and Schering Integrated in Scandinavia
On April 1 Bayer and Schering have been legally combined in Scandinavia. This leads to the formation of a new pharmaceutical organization within Bayer HealthCare. The division carries the name Bayer Schering Pharma and is the largest division within Bayer HealthCare.

"The combination of Bayer and Schering will strengthen our position in Denmark, Sweden, Norway and Iceland," said Mattias Norrman, Country Divisional Head for Bayer Schering Pharma in Scandinavia. "With our portfolio of innovative products such as the cancer drug Nexavar and Betaferon against multiple sclerosis, we are committed to providing the highest level of service to our customers."

"This is a compelling combination that fits into the strategy to strengthen our pharmaceutical business by focusing on specialty care. The acquisition is the largest purchase in Bayer's history, the change of name demonstrates to physicians, patients and our employees that we have strengthened Bayer HealthCare according to Bayer's mission: 'Science for a Better Life', said Arthur J. Higgins, Chairman of the Bayer Schering Pharma Management Board, and of the Executive Committee of Bayer HealthCare. "It is our vision to be recognized as a company that drives medical progress and applies science to create a better life for millions of people around the world."

Bayer Schering Pharma is headquartered in Berlin, Germany. The Scandinavian headquarters of the division will be placed in Stockholm. In 2006 the total sales of the combined businesses amounted in more than 7 billion euros. The businesses invested a total of 1.4 billion euros in research and development in 2006. Bayer Schering Pharma is among the top ten specialty pharmaceutical companies worldwide. Today the company is already the world market leader in hormonal contraception, and has leading positions in the fields of multiple sclerosis, hematology and cardiology, as well as in oncology and diagnostic imaging.

For further information please contact

Gitte Finnich Pedersen,
Head of Bayer Norden Corporate Communications
Tlf.: +45 45 23 50 07
e-mail: gitte.finnichpedersen.gf@bayer.dk

Bayer HealthCare

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide.

Bayer Schering Pharma

Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, Hematology/Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life.

In the Scandinavian countries Bayer Schering Pharma is part of Bayer Norden, a regional entity in the international Bayer AG group. Bayer Norden consists of Denmark, Sweden, Norway and Iceland as well as Estonia, Latvia and Lithuania with 475 employees, net sales of 731 mio. euro and a operating result of 15,8 mio. euro (2006).

Forward-looking statements
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.